目的探讨尤瑞克林治疗急性脑梗死的疗效及安全性。方法 86例急性脑梗死患者静脉滴注尤瑞克林0.15 PNA+0.9%生理盐水100 ml,给药1次/d,连续滴注7~14 d;采用神经功能缺损评分(NIHSS)标准评价患者治疗前后神经功能恢复情况及临床疗效,检测不良反应并考察其对血小板聚集率、血液粘稠度的影响。结果尤瑞克林治疗后,轻、中、重型患者NIHSS平均分均较治疗前显著降低(P<0.05),对轻型、中型和重型患者的有效率分别为85.4%、82.8%和66.7%,疗效显著;治疗后血小板聚集率和血液粘稠度显著降低(P<0.05),未见明显不良反应。结论尤瑞克林治疗急性脑梗死安全、有效,值得临床推广。 Objective To investigate the efficacy and safety of urelin in the treatment of acute cerebral infarction. Methods Eighty-six patients with acute cerebral infarction were infused intravenously with 0.15 ml of natriuretic chloride (PNA) and 0.9% normal saline (100 ml) once a day for 7 to 14 days. Neurological deficit score (NIHSS) Before and after treatment of neurological recovery and clinical efficacy, adverse reactions were measured and investigated its effect on platelet aggregation rate, blood viscosity. Results After treatment with uracil, the average NIHSS scores of patients with mild, moderate, and severe symptoms were significantly lower than those before treatment (P <0.05), and were 85.4%, 82.8% and 66.7% for patients with mild, moderate, The curative effect was remarkable. After treatment, the platelet aggregation rate and blood viscosity were significantly decreased (P <0.05), and no obvious adverse reaction was found. Conclusion The treatment of acute cerebral infarction with uracil is safe and effective and worthy of clinical promotion.